They have a proprietary True Single Molecule Sequencing system.
They are a small company with a few sales, Stanford, Rikon (Japan).

They have interest from international buyers, and they are probably
looking for partnership to help sell their system.

They are the best in the field if you consider their technology
and it's potential. Selling in the mid 2's.

This technology will be used not only in research but also
in clinical diagnostics. Once into clinical diagnostics, they will
greatly increase sales. They may be bought out.